The Belgian drugmaker pulled off a rare feat, retaining its independence while collecting a multibillion-dollar investment from Gilead. Now it needs to prove its partner's bet was well placed. Read more ➔

The rise of a new cancer drug portfolio, coupled with booming sales in China, have put AstraZeneca ahead of its pharma peers in 2019. Read more ➔

Along with other recently acquired cancer companies like Ignyta and Array, Loxo proved out a drug development model that Bilenker likens to baseball's "moneyball" thesis.  Read more ➔

If approved, the Alzheimer's drug would likely earn billions. But researchers are divided over whether Biogen's data show an unexpected benefit, or are just a statistical mirage. Read more ➔

A more active FTC, suggested by the surprise delay for Roche's takeover of Spark, could slow dealmaking in an industry that relies on big pharma buyouts. Read more ➔

While clouded by controversy, Novartis' launch of Zolgensma shows gene therapy can be successfully commercialized, even as questions of affordability remain paramount. Read more ➔

Whether or not the $74 billion acquisition succeeds for Bristol-Myers, its impact on biotech will be wide-reaching by erasing Celgene, one of the industry's most active dealmakers. Read more ➔